La cadena de opciones muestra datos clave de las opciones de acciones de Innate Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Innate Pharma..

Innate Pharma (NASDAQ:IPHA) Bolsa, Cadena de Opciones

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

<a href="https://www.benzinga.com/topic/ai-chips" target="_blank" rel="noreferrer noopener">Artificial intelligence chip stocks</a> including Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), Marvell Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>), Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), Arm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), and Micron Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), are trading higher Thursday in sympathy with Taiwan Semiconductor Manufacturing Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/news/earnings/25/01/43022654/taiwan-semiconductor-q4-earnings-3nm-and-5nm-nodes-lead-topline-growth-expands-margins-issues-strong-q1-outlook" target="_blank" rel="noreferrer noopener">upbeat quarterly print</a>.
Taiwan Semiconductor is the key contract chipmaker behind Nvidia&#8217;s graphics processing units&nbsp;(GPU) and Apple Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) smartphones.
However, on Wednesday, the Biden administration announced its <a href="https://www.benzinga.com/government/regulations/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report" target="_blank" rel="noreferrer noopener">latest semiconductor regulations</a>, including extended licensing requirements on companies like Taiwan Semiconductor, which manufactures chips, and packaging companies, citing national security threats.
Also Read: <a href="https://www.benzinga.com/media/25/01/42981814/apple-and-nvidia-supplier-taiwan-semiconductor-leads-semiconductor-market-with-64-share" target="_blank" rel="noreferrer noopener">Apple And Nvidia Supplier Taiwan Semiconductor Leads Semiconductor Market with 64% Share</a>
Chipmakers like Taiwan Semiconductor and&nbsp;Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>) must <a href="https://www.benzinga.com/25/01/43003008/taiwan-semi-samsung-intel-may-face-stricter-us-rules-on-chip-exports-to-china-over-security-concerns" target="_blank" rel="noreferrer noopener">ramp up due diligence</a> especially with China-based firms.
Washington imposed sanctions on 16 Chinese companies, including Sophgo Technologies, for building their country&#8217;s chip industry, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-15/us-unveils-new-rules-to-restrict-flow-of-advanced-chips-to-china?srnd=phx-technology&amp;sref=TBDibEcD" target="_blank" rel="noreferrer noopener">cites</a> the Commerce Department.
On Monday, the U.S. disclosed sanctions on the sale of AI chips by Nvidia and other advanced makers to data centers in most countries.
The rules for AI chips follow&nbsp;controls&nbsp;announced in December that aim to block Beijing&#8217;s access to <a href="https://www.benzinga.com/government/24/08/40198085/huawei-and-baidu-increase-samsung-hbm-purchases-as-us-curbs-loom" target="_blank" rel="noreferrer noopener">high-bandwidth memory</a> chips from Micron.
Semiconductor chip stocks enjoyed a massive upside in 2024, backed by the AI boom.
A third of the top ten global companies with valuations above $1 trillion in 2024 came from the chip industry.
Investors can gain exposure to stocks of companies that manufacture semiconductors through ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>) and Invesco PHLX Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXQ#NASDAQ">SOXQ</a>).
Also Read:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/43008511/broadcoms-latest-san-switch-offers-scalable-energy-efficient-solution-for-growing-storage-demands" target="_blank" rel="noreferrer noopener">Broadcom&#8217;s Latest SAN Switch Offers Scalable, Energy-Efficient Solution for Growing Storage Demands</a></li>
</ul>
Photo via Shutterstock

Large Cap

News

Tech

Media

AAPL

AVGO

MRVL

NVDA

QCOM

SOXQ

SSNLF

AI Chip Stocks Gain Momentum On Taiwan Semiconductor Performance;  Biden's Semiconductor Sanctions Kick In

Needham analyst Bernie McTernan reiterates ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) from Hold to Hold.

Reiteration

Analyst Ratings

TDUP

Needham Reiterates Hold on ThredUpto Hold

Needham analyst Charles Shi reiterates Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) with a Buy and maintains $225 price target.

Price Target

Needham Reiterates Buy on Taiwan Semiconductor, Maintains $225 Price Target

Northland Capital Markets analyst Bobby Brooks maintains Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) with a Outperform and raises the price target from $28 to $31.

Northland Capital Markets Maintains Outperform on Vitesse Energy, Raises Price Target to $31

Seaport Global analyst Daniel Mckenzie upgrades Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) from Neutral to Buy and announces $5 price target.

Upgrades

AZUL

Seaport Global Upgrades Azul to Buy, Announces $5 Price Target

Needham analyst Chris Pierce reiterates EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) from Hold to Hold.

EVGO

Needham Reiterates Hold on EVgoto Hold

PNC Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) reported fourth-quarter revenue increase of 4% year-over-year to $5.57 billion, beating the <a href="https://www.benzinga.com/pressreleases/25/01/n43023633/pnc-reports-full-year-2024-net-income-of-6-0-billion-13-74-diluted-eps" target="_blank" rel="noreferrer noopener">consensus of $5.50 billion</a>. Revenue growth was led by higher net interest income and noninterest income.
Net interest income grew 4% year over year to $3.52 billion, thanks to a decline in funding costs and the continued repricing of fixed-rate assets. The net interest margin stood at 2.75%, 9 basis points higher year over year.
Noninterest income grew 4% to $2.04 billion, led by higher fee income (+3% Y/Y) thanks to strong growth in capital markets and advisory segment. EPS of $3.77 topped <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">the consensus of $3.33</a>.
The company reported a provision for credit losses of&nbsp;$156 million in the quarter (vs.&nbsp;$232 million a year ago) on improved macroeconomic factors and portfolio activity.&nbsp;
CET1 capital ratio stood at&nbsp;10.5% vs.&nbsp;9.9% in the prior year quarter.&nbsp;
On January 3, 2025, PNC&#8217;s board of directors declared a quarterly cash dividend on common stock of&nbsp;$1.60, payable on February 5, 2025, to shareholders of&nbsp;record <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n42791132/pnc-declares-dividend-of-1-60-on-common-stock" rel="noreferrer noopener">as of&nbsp;January 15, 2025</a>.
PNC returned&nbsp;$0.9&nbsp;billion of capital to shareholders, comprising share repurchases over&nbsp;$0.2&nbsp;billion in the quarter.
The company expects share repurchase activity for the&nbsp;first quarter&nbsp;of 2025 to match recent quarterly averages.
<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">Guidance</a><a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">:</a> For the&nbsp;first quarter, the bank expects average loans to be down 1%, total revenue to be lower 1% – 2%, and net interest income to be&nbsp;down <a target="_blank" href="https://d1io3yog0oux5.cloudfront.net/_5a0874e2a3dfe89249dbc4eeb815a72a/pnc/db/2250/21537/presentation/4Q24+Earnings+Slides_Final.pdf" rel="noreferrer noopener">2%</a> – 3%&nbsp;sequentially.
Investors can gain exposure to the stock via&nbsp;IShares U.S. Regional Banks ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAT#NYSE">IAT</a>) and&nbsp;Davis Fundamental ETF Trust Davis Select Financial ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DFNL#BATS">DFNL</a>).
Price Action: PNC shares are down 1.72% at $197.00&nbsp; premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43007354/big-banks-crush-q4-earnings-forecasts-financial-stocks-set-for-biggest-1-day-rally-since-trumps-election" target="_blank" rel="noreferrer noopener">Big Banks Crush Q4 Earnings Forecasts: Financial Stocks Set For Biggest 1-Day Rally Since Trump&#8217;s Election</a></li>
</ul>

Earnings

Equities

Guidance

Dividends

Buybacks

DFNL

iShares Dow Jones US Regional Banks Index Fund

PNC Financial Q4 Earnings: Credit Losses Provision Dips, Forecasts Sequential Fall In Q1 Revenue And Loans

Stagwell Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) shares are trading slightly <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/n43022240/stagwell-stgw-acquires-adk-global-integrated-marketing-subsidiary-of-adk-holdings-inc-bolstering-g" rel="noreferrer noopener">higher in the premarket session on Thursday.</a>
Today, the company has announced its intent to acquire ADK GLOBAL, a network of marketing subsidiaries managed by ADK Holdings Inc.
Based in Japan, ADK GLOBAL operates in 10 markets worldwide, offering integrated marketing solutions with a deep understanding of local markets, media, and consumers.
The acquisition marks a significant expansion of Stagwell&#8217;s global presence, particularly in the Asia-Pacific region, where ADK GLOBAL has a strong footprint.
The deal will increase Stagwell&#8217;s regional staff to over 2,000 team members across 14 APAC countries, including China, India, Japan, South Korea, and Vietnam.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43023600/us-stocks-could-higher-open-despite-mixed-futures-335-concentration-in-magnificent-seven-stocks-rings-alarm" rel="noreferrer noopener">US Stocks Could Open Higher After Big Banks Report Strong Earnings: Mag 7 Now Account For A Third Of S&amp;P 500&#8217;s Market Capitalization, Raising Alarms</a>
With the addition of ADK GLOBAL, Stagwell will expand its AI-powered marketing solutions and enhance its ability to deliver creative, media, and PR services for both local and global clients.
These solutions will support brands such as LG, Adidas, and Shanghai Disney Resort, helping them achieve impactful results in the digital marketing space.
Mark Penn, Chairman and CEO of Stagwell, emphasized that the acquisition will strengthen Stagwell&#8217;s APAC division and enable the company to offer a comprehensive suite of marketing services tailored to local, regional, and global clients.
This collaboration aligns with Stagwell&#8217;s goal to enhance its global marketing capabilities, providing clients with digital solutions while expanding its market presence in the rapidly growing APAC region.
Price Action: STGW shares are trading higher by 3.12% to $6.60 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43021065/cash-app-parent-block-inc-eyes-395-upside-bofa-believes-us-centric-re-acceleration-story-will-drive-the-stock" target="_blank" rel="noreferrer noopener">Jack Dorsey's Block Eyes Over 39% Upside: BofA Says US-Centric Re-Acceleration Story Will Drive The Stock</a></li>
</ul>
Photo via Shutterstock.

Markets

Movers

General

STGW

Stagwell Agrees To Acquire ADK GLOBAL, Expanding APAC Footprint

Needham analyst Chris Pierce reiterates Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) with a Buy and maintains $11 price target.

ACHR

Needham Reiterates Buy on Archer Aviation, Maintains $11 Price Target

Rosenblatt analyst Steve Frankel maintains Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) with a Buy and maintains $28 price target.

IMAX

Rosenblatt Maintains Buy on Imax, Maintains $28 Price Target

Stifel analyst Benjamin Nolan maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Buy and lowers the price target from $262 to $253.

Stifel Maintains Buy on Union Pacific, Lowers Price Target to $253

Needham analyst Bernie McTernan reiterates Compass (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) with a Buy and maintains $10 price target.

COMP

Needham Reiterates Buy on Compass, Maintains $10 Price Target

Morgan Stanley Reports Q4 2024 Investment Banking Revenues Up 25%; Equity Net Revenues Up 51%; Fixed Income Net Revenues Up 35%

Rosenblatt analyst Barton Crockett maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Neutral and maintains $680 price target.

NFLX

Rosenblatt Maintains Neutral on Netflix, Maintains $680 Price Target

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) reported quarterly earnings of $2.22 per share which beat the analyst consensus estimate of $1.70 by 30.59 percent. The company reported quarterly sales of $16.22 billion which beat the analyst consensus estimate of $15.03 billion by 7.92 percent. This is a 25.80 percent increase over sales of $12.90 billion the same period last year.

Earnings Beats

Morgan Stanley Q4 2024 Adj EPS $2.22 Beats $1.70 Estimate, Sales $16.22B Beat $15.03B Estimate

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) with a Buy and maintains $5.5 price target.

LPTX

HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $5.5 Price Target

Based on its collaborative, ongoing discussions with regulatory authorities, Core believes Leer South will be able to resume development work with continuous miners within the next three months, and to resume longwall mining mid-year.

Core Natural Reveals Steps To Temporarily Seal Leer South Mine's Active Longwall Panel In Order To Extinguish Isolated Combustion-related Activity

Stifel analyst Benjamin Nolan maintains Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) with a Hold and lowers the price target from $82 to $76.

Stifel Maintains Hold on Canadian Pacific Kansas, Lowers Price Target to $76

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">CVR Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>)</h3>
<ul>
<li>Dividend Yield: 9.41%</li>
<li>Goldman Sachs analyst Neil Mehta maintained a Sell rating and cut the price target from $24 to $21 on Dec. 6, 2024. This analyst has an accuracy rate of 69%.</li>
<li>JP Morgan analyst Phil Gresh maintained an Underweight rating and lowered the price target from $26 to $23 on Oct. 2, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: Icahn Enterprises L.P. and Icahn Enterprises Holdings L.P. announced results of tender offer for up to 17,753,322 shares of common stock of CVR Energy.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011625&amp;t=be2bearmibe3na1">latest CVI news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073057/image-107.png" alt="" class="wp-image-736634" style="width:724px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073057/image-107.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073057/image-107-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073057/image-107-768x692.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">DHT Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHT#NYSE">DHT</a>)</h3>
<ul>
<li>Dividend Yield: 7.73%</li>
<li>Jefferies analyst Omar Nokta maintained a Buy rating with a price target of $14 on Nov. 13, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Benjamin Nolan maintained a Hold rating and cut the price target from $13 to $11 on Oct. 23, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: DHT Holdings announced that the Company has purchased 1,481,383 of its own shares in the open market, equivalent to 0.9% of its outstanding shares, at an average price of $8.8899.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011625&amp;t=be2bearmibe3na1"> latest DHT news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="915" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073209/image-108.png" alt="" class="wp-image-736637" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073209/image-108.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073209/image-108-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073209/image-108-768x693.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<h3 class="wp-block-heading">Ardmore Shipping Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASC#NYSE">ASC</a>)</h3>
<ul>
<li>Dividend Yield: 8.16%</li>
<li>Jefferies analyst Omar Nokta maintained a Buy rating and cut the price target from $20 to $17 on Nov. 14, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Benjamin Nolan downgraded the stock from Buy to Hold and cut the price target from $24 to $17 on Oct. 23, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Nov. 6, Ardmore Shipping posted downbeat quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011625&amp;t=be2bearmibe3na1">ASC news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011625&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="903" height="823" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073241/image-109.png" alt="" class="wp-image-736641" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073241/image-109.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073241/image-109-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16073241/image-109-768x700.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42998360/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

Wall Street's Most Accurate Analysts' Views On 3 Energy Stocks With Over 7% Dividend Yields

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Buy and maintains $21 price target.

ITOS

HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $21 Price Target

Innate Pharma S.A. 2024 Q3 - Results - Earnings Call Presentation

Innate Pharma reports 9M results

Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript

Innate Pharma (IPHA) announced the publication in Science Immunology of preclinical data demonstrating the potential of IPH6501, Innate's proprieta...

Innate Pharma publishes IPH6501 data in Science Immunology

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Innate Pharma (IPHA) with the Institute for Follicular Lymphoma, or IFLI, announced that they have entered into an agreement to clinically study th...

Innate Pharma partners with IFLI to study IPH6501, to receive $3M upfront

Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024

Innate Pharma (IPHA) announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma, or CTCL,...

Innate Pharma announces new data from TELLOMAK study

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Innate Pharma (IPHA – Research Report) and keeping the price target ...

Positive Outlook for Innate Pharma: Buy Rating Supported by Promising Lacutamab Phase 2 Results and Strong Financial Position

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AGIO

CMRX

IPHA

IPHYF

MCRB

Press Releases

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Innate Pharma Releases Its 2025 Financial Calendar

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Comments

Innate Pharma

Innate Pharma (IPHA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL